First Header Logo Second Header Logo

Caio Max Rocha Lima

Concepts (292)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Pancreatic Neoplasms
33
2016
134
6.540
Why?
Antineoplastic Combined Chemotherapy Protocols
42
2017
458
6.250
Why?
Deoxycytidine
28
2014
68
3.500
Why?
Camptothecin
19
2014
51
2.930
Why?
Antineoplastic Agents
18
2016
608
2.040
Why?
Colorectal Neoplasms
13
2015
215
2.040
Why?
Lung Neoplasms
20
2015
414
1.750
Why?
Adenocarcinoma
12
2015
308
1.680
Why?
Neoplasms
12
2016
729
1.360
Why?
Taxoids
11
2017
59
1.290
Why?
Fluorouracil
12
2014
81
1.260
Why?
Antimetabolites, Antineoplastic
8
2010
49
1.210
Why?
Organoplatinum Compounds
8
2014
46
1.110
Why?
Carcinoma, Small Cell
8
2012
25
1.100
Why?
Carcinoma, Non-Small-Cell Lung
10
2006
101
1.100
Why?
Middle Aged
57
2017
11839
0.950
Why?
Antibodies, Monoclonal
10
2013
246
0.920
Why?
Aged
52
2017
10314
0.910
Why?
Humans
87
2017
32116
0.900
Why?
Paclitaxel
5
2013
67
0.880
Why?
Adult
44
2017
9381
0.800
Why?
Treatment Outcome
27
2017
3306
0.760
Why?
Male
56
2017
19218
0.730
Why?
Neoadjuvant Therapy
7
2012
67
0.710
Why?
Salvage Therapy
4
2011
134
0.710
Why?
Colonic Neoplasms
3
2010
71
0.700
Why?
Female
56
2017
20016
0.690
Why?
Chemotherapy, Adjuvant
8
2015
190
0.690
Why?
Neoplasm Metastasis
7
2014
220
0.690
Why?
Disease-Free Survival
11
2017
317
0.650
Why?
Antineoplastic Agents, Phytogenic
4
2005
37
0.650
Why?
Gastrointestinal Stromal Tumors
5
2010
12
0.650
Why?
Drug Administration Schedule
11
2016
276
0.620
Why?
Survival Analysis
11
2014
483
0.600
Why?
Cancer Vaccines
2
2014
24
0.580
Why?
Leucovorin
3
2012
24
0.580
Why?
Indoles
4
2016
56
0.580
Why?
Pyrroles
4
2016
55
0.570
Why?
Aged, 80 and over
24
2017
3990
0.560
Why?
Maximum Tolerated Dose
10
2014
62
0.560
Why?
Carcinoma, Pancreatic Ductal
2
2016
19
0.560
Why?
Neoplasm Recurrence, Local
7
2017
367
0.550
Why?
Carcinoma
3
2012
91
0.550
Why?
Neoplasm Staging
11
2014
447
0.540
Why?
Palliative Care
2
2010
52
0.530
Why?
Protein Kinase Inhibitors
3
2012
85
0.520
Why?
Endosonography
4
2011
56
0.520
Why?
Topotecan
4
2009
17
0.500
Why?
Angiogenesis Inhibitors
3
2016
36
0.490
Why?
Gastrins
1
2014
4
0.480
Why?
Stomach Neoplasms
3
2014
84
0.460
Why?
Esophageal Neoplasms
3
2011
35
0.450
Why?
Survival Rate
15
2012
877
0.450
Why?
Albumins
1
2013
45
0.430
Why?
Cell Cycle
1
2012
77
0.410
Why?
Antimitotic Agents
1
2012
2
0.410
Why?
Rectal Neoplasms
2
2009
18
0.410
Why?
Oligopeptides
1
2012
45
0.400
Why?
Clinical Trials as Topic
6
2008
301
0.390
Why?
Piperidines
2
2012
118
0.390
Why?
Biopsy, Fine-Needle
4
2011
53
0.390
Why?
Biliary Tract Neoplasms
2
2017
10
0.370
Why?
Carcinoma, Squamous Cell
1
2012
154
0.370
Why?
Cytoskeletal Proteins
1
2010
15
0.370
Why?
Infusions, Intravenous
5
2014
100
0.360
Why?
Drug Therapy
1
2010
16
0.350
Why?
Biopsy, Needle
2
2008
93
0.340
Why?
DNA Methylation
1
2010
141
0.340
Why?
Prognosis
9
2015
1497
0.330
Why?
Etoposide
3
2007
34
0.330
Why?
CA-19-9 Antigen
2
2013
6
0.320
Why?
Receptors, Vascular Endothelial Growth Factor
1
2008
21
0.310
Why?
Emphysematous Cholecystitis
1
2007
1
0.290
Why?
Drug Delivery Systems
1
2008
104
0.290
Why?
Carcinoma, Neuroendocrine
1
2007
12
0.290
Why?
Quinazolines
4
2008
38
0.290
Why?
Ultrasonography, Interventional
2
2011
53
0.290
Why?
Drug Resistance, Neoplasm
3
2012
104
0.270
Why?
Mediastinal Neoplasms
1
2006
13
0.270
Why?
Ablation Techniques
2
2016
25
0.260
Why?
Lymph Nodes
1
2006
107
0.260
Why?
Randomized Controlled Trials as Topic
8
2015
510
0.260
Why?
Electroporation
2
2016
14
0.250
Why?
Combined Modality Therapy
7
2010
560
0.240
Why?
Retrospective Studies
11
2016
3510
0.240
Why?
Disease Progression
5
2010
594
0.240
Why?
Coronary Vasospasm
1
2004
4
0.230
Why?
Diarrhea
3
2014
60
0.230
Why?
Hospitals, General
1
2013
4
0.230
Why?
Cancer Care Facilities
1
2013
10
0.230
Why?
Follow-Up Studies
7
2014
2265
0.220
Why?
Drug Synergism
3
2014
66
0.220
Why?
Liver Neoplasms
3
2014
155
0.220
Why?
Carboplatin
5
2007
48
0.210
Why?
Genetic Markers
1
2002
124
0.200
Why?
Vomiting
2
2014
24
0.170
Why?
Tomography, X-Ray Computed
3
2016
919
0.170
Why?
Nausea
2
2014
53
0.170
Why?
Pancreatic Diseases
2
2010
18
0.170
Why?
Protein-Tyrosine Kinases
2
2010
40
0.170
Why?
Gastrointestinal Neoplasms
2
2011
31
0.160
Why?
Clinical Trials, Phase III as Topic
4
2002
30
0.160
Why?
European Continental Ancestry Group
2
2014
1166
0.160
Why?
Piperazines
2
2010
54
0.150
Why?
Pyrimidines
2
2010
65
0.150
Why?
Pyridines
2
2008
76
0.150
Why?
Endothelins
1
2017
4
0.150
Why?
Brain Neoplasms
1
2003
638
0.140
Why?
Radiography, Interventional
1
2016
37
0.140
Why?
Epothilones
1
2016
3
0.130
Why?
Tubulin Modulators
1
2016
10
0.130
Why?
Young Adult
4
2014
2666
0.130
Why?
African Americans
2
2014
1425
0.130
Why?
Pancreatectomy
2
2012
27
0.130
Why?
Clinical Trials, Phase II as Topic
4
2006
14
0.130
Why?
Splenic Artery
1
2015
11
0.130
Why?
Thrombocytopenia
1
2015
30
0.130
Why?
Breast Neoplasms
3
2012
765
0.120
Why?
Neutropenia
1
2014
29
0.120
Why?
Electrochemotherapy
1
2014
3
0.120
Why?
Injections, Intramuscular
1
2014
43
0.120
Why?
Embolization, Therapeutic
1
2015
86
0.120
Why?
Sensitivity and Specificity
4
2011
582
0.120
Why?
Peptide Fragments
1
2017
399
0.120
Why?
Time Factors
4
2016
2151
0.120
Why?
Perception
1
2014
101
0.110
Why?
Immunohistochemistry
2
2012
538
0.110
Why?
Pancreas
2
2011
103
0.110
Why?
Receptor, erbB-2
1
2014
65
0.110
Why?
Quality of Life
3
2004
946
0.110
Why?
Arsenic
1
2013
3
0.110
Why?
Hematologic Diseases
2
2004
23
0.110
Why?
Proto-Oncogene Proteins c-kit
2
2010
24
0.110
Why?
Trisaccharides
1
2012
1
0.110
Why?
Deoxyglucose
1
2012
16
0.110
Why?
Immunotherapy, Active
1
2012
6
0.110
Why?
Cyclin-Dependent Kinases
1
2012
9
0.110
Why?
Attitude to Health
1
2014
166
0.110
Why?
Pancreaticoduodenectomy
1
2012
20
0.110
Why?
Benzamides
2
2010
50
0.110
Why?
Drug Design
1
2012
43
0.110
Why?
Prospective Studies
7
2014
2284
0.100
Why?
Clinical Trials, Phase I as Topic
3
2004
11
0.100
Why?
Environmental Exposure
1
2013
91
0.100
Why?
Catheter Ablation
1
2012
67
0.100
Why?
Adolescent
4
2014
3569
0.100
Why?
Algorithms
2
2012
495
0.100
Why?
Triazines
1
2011
3
0.100
Why?
Boronic Acids
2
2008
8
0.100
Why?
Alanine
1
2011
27
0.100
Why?
Pyrazines
2
2008
13
0.100
Why?
Cell Line, Tumor
2
2010
726
0.100
Why?
Celiac Plexus
1
2011
3
0.100
Why?
Diagnosis, Differential
3
2010
517
0.090
Why?
Family
1
2011
117
0.090
Why?
Metalloproteases
1
2010
4
0.090
Why?
Diagnostic Imaging
2
2008
94
0.090
Why?
CARD Signaling Adaptor Proteins
1
2010
5
0.090
Why?
Cyclooxygenase 2 Inhibitors
1
2010
15
0.090
Why?
Abdominal Pain
1
2011
44
0.090
Why?
Azacitidine
1
2010
28
0.090
Why?
Gene Silencing
1
2010
48
0.090
Why?
Proto-Oncogene Proteins c-akt
1
2010
70
0.090
Why?
Mutation
2
2010
489
0.090
Why?
Transfection
1
2010
191
0.090
Why?
Vascular Endothelial Growth Factor A
1
2010
112
0.090
Why?
Caregivers
1
2011
114
0.090
Why?
Biliary Tract Diseases
1
2010
12
0.090
Why?
Cisplatin
3
2011
76
0.090
Why?
Cholangiopancreatography, Endoscopic Retrograde
1
2010
32
0.090
Why?
Promoter Regions, Genetic
1
2010
208
0.090
Why?
Radiation Tolerance
1
2009
24
0.090
Why?
Proteins
1
2010
144
0.080
Why?
Models, Genetic
1
2009
94
0.080
Why?
Lymphatic Metastasis
2
2007
166
0.080
Why?
Benzenesulfonates
1
2008
3
0.080
Why?
Phenylurea Compounds
1
2008
10
0.080
Why?
Niacinamide
1
2008
8
0.080
Why?
Gene Expression
1
2009
338
0.080
Why?
Depression
1
2011
445
0.080
Why?
DNA Topoisomerases, Type I
2
2006
9
0.080
Why?
Endoscopy
1
2008
58
0.080
Why?
Head and Neck Neoplasms
1
2009
130
0.080
Why?
Patient Care Team
1
2008
129
0.070
Why?
Administration, Oral
2
2007
187
0.070
Why?
Cholecystostomy
1
2007
1
0.070
Why?
Hyperbilirubinemia
1
2007
2
0.070
Why?
Leukocytosis
1
2007
7
0.070
Why?
Phosphorylcholine
1
2007
5
0.070
Why?
Probability
1
2007
159
0.070
Why?
Radiography
2
2012
376
0.070
Why?
Risk Factors
2
2014
3880
0.070
Why?
Proportional Hazards Models
3
2016
753
0.070
Why?
Acute Disease
1
2007
253
0.070
Why?
Feasibility Studies
1
2007
294
0.070
Why?
Sarcoma
1
2007
73
0.070
Why?
Equipment Design
1
2006
171
0.070
Why?
Models, Statistical
1
2006
175
0.060
Why?
Alkyl and Aryl Transferases
1
2004
2
0.060
Why?
Thalidomide
1
2005
31
0.060
Why?
Quinolones
1
2004
7
0.060
Why?
Dose-Response Relationship, Drug
4
2010
633
0.060
Why?
Electrocardiography
2
2012
605
0.060
Why?
Enterocolitis, Neutropenic
1
2004
1
0.060
Why?
Aniline Compounds
1
2014
18
0.060
Why?
Patient Selection
2
2007
276
0.060
Why?
Proto-Oncogene Proteins c-bcl-2
1
2014
34
0.060
Why?
Imidazoles
1
2004
91
0.060
Why?
Anti-Bacterial Agents
1
2007
324
0.060
Why?
Signal Transduction
1
2008
682
0.060
Why?
Lymphocytes
1
2004
57
0.060
Why?
Sulfonamides
1
2014
67
0.060
Why?
Enzyme Inhibitors
1
2004
166
0.060
Why?
Hospitals, Voluntary
1
2013
2
0.060
Why?
Epidermal Growth Factor
1
2003
27
0.060
Why?
Blood-Brain Barrier
1
2003
48
0.050
Why?
SEER Program
3
2007
30
0.050
Why?
Survival
1
2002
13
0.050
Why?
Poverty
1
2013
115
0.050
Why?
Neoplasms, Unknown Primary
1
2002
6
0.050
Why?
Safety
1
2002
77
0.050
Why?
Age Distribution
1
2002
206
0.050
Why?
Lymphoma, Non-Hodgkin
1
2001
22
0.050
Why?
Stress, Psychological
2
2014
222
0.050
Why?
Granulocyte Colony-Stimulating Factor
1
2001
24
0.050
Why?
Hematologic Neoplasms
1
2001
35
0.050
Why?
Longitudinal Studies
2
2014
770
0.050
Why?
Multicenter Studies as Topic
1
2000
105
0.050
Why?
Florida
2
2013
37
0.040
Why?
Area Under Curve
2
2010
93
0.040
Why?
Tumor Burden
1
2016
58
0.040
Why?
Reproducibility of Results
2
2010
765
0.030
Why?
Incidence
2
2013
1199
0.030
Why?
Neovascularization, Pathologic
1
2016
82
0.030
Why?
Registries
2
2007
298
0.030
Why?
Georgia
1
2014
14
0.030
Why?
Family Relations
1
2014
23
0.030
Why?
Epirubicin
1
2014
1
0.030
Why?
Water Supply
1
2013
10
0.030
Why?
Positron-Emission Tomography
1
2014
163
0.030
Why?
Antigens, Neoplasm
1
2013
45
0.030
Why?
Cluster Analysis
1
2013
125
0.030
Why?
Receptor, IGF Type 1
1
2012
7
0.030
Why?
Placebos
1
2012
63
0.030
Why?
Rare Diseases
1
2012
21
0.030
Why?
Neoplasm Proteins
1
2013
148
0.030
Why?
Esophagogastric Junction
1
2011
7
0.020
Why?
Aneuploidy
1
2011
10
0.020
Why?
Chromosomes, Human, Pair 17
1
2011
13
0.020
Why?
Chromosomes, Human, Pair 9
1
2011
16
0.020
Why?
Chromosomes, Human, Pair 7
1
2011
15
0.020
Why?
In Situ Hybridization, Fluorescence
1
2011
40
0.020
Why?
Sequence Deletion
1
2011
40
0.020
Why?
Chromosomes, Human, Pair 3
1
2011
28
0.020
Why?
Vascular Endothelial Growth Factor Receptor-2
1
2011
23
0.020
Why?
Tissue Distribution
1
2011
61
0.020
Why?
Autonomic Nerve Block
1
2011
10
0.020
Why?
Analgesia
1
2011
29
0.020
Why?
Logistic Models
1
2013
783
0.020
Why?
Drug Therapy, Combination
1
2011
288
0.020
Why?
Social Support
1
2011
182
0.020
Why?
Antigens, Tumor-Associated, Carbohydrate
1
2010
3
0.020
Why?
Half-Life
1
2010
23
0.020
Why?
Biliary Tract
1
2010
7
0.020
Why?
Blood Glucose
1
2012
494
0.020
Why?
Pain Measurement
1
2011
350
0.020
Why?
Oligonucleotide Array Sequence Analysis
1
2009
160
0.020
Why?
Sample Size
1
2008
38
0.020
Why?
Linear Models
1
2009
449
0.020
Why?
United States
2
2007
3976
0.020
Why?
Muscle Neoplasms
1
2007
8
0.020
Why?
Endoscopy, Gastrointestinal
1
2007
25
0.020
Why?
Muscle, Smooth
1
2007
68
0.020
Why?
Antiemetics
1
2007
6
0.020
Why?
DNA Topoisomerases, Type II
1
2006
4
0.020
Why?
Bone Neoplasms
1
2007
111
0.020
Why?
Population Surveillance
1
2007
125
0.020
Why?
Case-Control Studies
1
2008
898
0.020
Why?
Farnesyltranstransferase
1
2004
2
0.020
Why?
Multivariate Analysis
1
2007
684
0.020
Why?
Inhibitory Concentration 50
1
2004
22
0.020
Why?
Models, Chemical
1
2004
34
0.020
Why?
Leukocytes, Mononuclear
1
2004
56
0.010
Why?
Flavonoids
1
2004
18
0.010
Why?
Fatal Outcome
1
2004
83
0.010
Why?
Peritoneal Neoplasms
1
2007
259
0.010
Why?
Severity of Illness Index
1
2007
881
0.010
Why?
Cohort Studies
1
2007
1817
0.010
Why?
Vinblastine
1
2000
6
0.010
Why?
Remission Induction
1
2000
84
0.010
Why?
Child
1
2007
2442
0.010
Why?
Tumor Cells, Cultured
1
1999
171
0.010
Why?
Rocha Lima's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (292)
Explore
_
Similar People (47)
Explore
_
Same Department Expand Description
Explore
_